Merck & Co Inc


  • Boehringer and Lilly will continue to jointly develop and market these drugs in 17 countries, including the United States, they said in a statement on Wednesday. A new insulin glargine product, which is approved in Europe, has won tentative approval in the United States. Sanofi SA said on Tuesday that growth in sales of its diabetes drugs would stall next year due...

  • Most active New York Stock Exchange-traded stocks Tuesday, 28 Oct 2014 | 1:25 PM ET

    NEW YORK— A look at New York Stock Exchange 10 most-active stocks at the close of trading:. Bank of America Corp. rose 1.3 percent to $16.80 with 67,921,300 shares traded. Cliffs Natural Resources Inc. rose 22.2 percent to $11.29 with 37,589,000 shares traded.

  • BUSINESS-NEWS-SCHEDULE AT 1330 GMT /9.30 AM ET Monday, 27 Oct 2014 | 10:08 AM ET

    MILAN- Italy's Monte dei Paschi di Siena is likely to try to plug a capital shortfall uncovered by Europe- wide stress tests through asset sales and possibly another cash call, but longer term a takeover could be inevitable. LONDON- Europe's banking healthcheck showed countries and lenders are implementing global capital rules at vastly different speeds, and...

  • Patent expirations weigh on Merck     Monday, 27 Oct 2014 | 9:31 AM ET

    The "Squawk on the Street" crew discusses pressures facing Merck in regards to drugs coming off patent, and the play on pharma companies.

  • Checkup on big pharma     Monday, 27 Oct 2014 | 8:15 AM ET

    Barbara Ryan, FTI Consulting, breaks down the numbers on Merck's quarterly results as the company appears to be reaping the rewards of R&D. Also a look ahead to Pfizer's earnings

  • Early Movers: MRK, AGN, BABA, TSLA, F & more Monday, 27 Oct 2014 | 8:01 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Merck, Twitter earnings eyed on Wall Street Monday, 27 Oct 2014 | 7:19 AM ET

    Wall Street looked set for a lower open on Monday, as traders focused on big third-quarter earnings from Merck, T-Mobile US and Twitter.

  • Merck 3Q adjusted profit tops analysts' estimates Monday, 27 Oct 2014 | 7:09 AM ET

    Merck also announced on Monday that the Food and Drug Administration gave breakthrough therapy designation to Keytruda for advanced non-small cell lung cancer that has progressed on or following platinum-based chemotherapy. Analysts surveyed by Zacks Investment Research expected earnings of 88 cents per share. Revenue declined to $10.56 billion from...

  • Merck, Twitter earnings in focus on Wall Street Monday, 27 Oct 2014 | 6:17 AM ET

    Wall Street looked set for a lower open on Monday, ahead of big third-quarter earnings like Merck, T-Mobile US and Twitter.

  • Trading could get scary next week as Fed day looms Friday, 24 Oct 2014 | 6:48 PM ET
    A trader works on the floor of the New York Stock Exchange, Oct. 24, 2014.

    The Fed is expected to end its quantitative easing program—the much-anticipated action that's been at the very heart of the market's fears.

  • Cramer: Ebola, the Fed and earnings, oh my Friday, 24 Oct 2014 | 6:15 PM ET

    Can the bull market continue? In preparation for earnings season to continue next week, Jim Cramer gives his take on what to expect.

  • Your first trade for Monday Friday, 24 Oct 2014 | 5:37 PM ET

    The "Fast Money" traders share their final trades of the day.

  • Oct 24- Bristol-Myers Squibb Co reported better-than-expected third-quarter results, as sizzling sales of its treatments for blood clots, cancer and arthritis helped offset sharply higher taxes. That compared with $692 million, or 42 cents per share, in the year-earlier period. Bristol-Myers, along with Merck& Co Inc, Roche Holding AG and AstraZeneca Plc are...

  • Your first trade for Thursday Wednesday, 22 Oct 2014 | 6:03 PM ET

    The "Fast Money" traders share their final trades of the day.

  • BUSINESS-NEWS-SCHEDULE AT 0830 GMT / 4.30 AM ET Friday, 17 Oct 2014 | 5:02 AM ET

    LONDON- World stocks hit a nine-month low but oil and southern European bonds are off their week's lows, as investors begin to dust themselves off after one of the most volatile spells in world markets in years. LONDON- The Bank of England may need to keep interest rates lower for longer than previously thought to reduce the chance of Britain's economy slipping...

  • LONDON, Oct 14- GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process. Britain's biggest drug maker is looking to divest the mature products in a bid to improve its growth profile and wants to dispose of...

  • Stocks plunge; Nasdaq Composite near correction Monday, 13 Oct 2014 | 4:08 PM ET

    Stocks rose Monday after last week's rout that came as investors fretted signs of a slowing global economy.

  • Cramer: Activists are picking on the wrong chiefs Thursday, 9 Oct 2014 | 6:25 PM ET
    Jim Cramer on Mad Money.

    Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention

  • Traders on the floor of the New York Stock Exchange.

    U.S. stocks ended about 2 percent higher on Wednesday as markets extended gains on the FOMC minutes and recovered from Tuesday's selloff.

  • NEW YORK, Oct 7- Bristol-Myers Squibb Co on Tuesday said it is no longer seeking U.S. approval for an oral two-drug combination to treat hepatitis C because of competition from rival drugs that require treatment for half as long and have shown higher cure rates. In addition, Bristol-Myers' drug faced stiff competition from products being developed by rival...